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Abstract The purpose of this study was to investigate
how renal loss of both C-peptide and glucose during oral
glucose tolerance test (OGTT) relate to and affect plasma-
derived oral minimal model (OMM) indices. All individ-
uals were recruited during family screening between
August 2007 and January 2011 and underwent a 3.5-h
OGTT, collecting nine plasma samples and urine during
OGTT. We obtained the following three subgroups: nor-
moglycemic, at risk, and T2D. We recruited South Asian
and Caucasian families, and we report separate analyses if
differences occurred. Plasma glucose, insulin, and C-pep-
tide concentrations were analyzed as AUCs during OGTT,
OMM estimate of renal C-peptide secretion, and OMM
beta-cell and insulin sensitivity indices were calculated to
obtain disposition indices. Post-glucose load glucose and
C-peptide in urine were measured and related to plasma-
based indices. Urinary glucose corresponded well with
plasma glucose AUC (Cau r = 0.64, P\ 0.01; SA r =
0.69, P\ 0.01), SI (Cau r = -0.51, P\ 0.01; SA r =
-0.41, P\ 0.01), Udynamic (Cau r = -0.41, P\ 0.01; SA
r = -0.57, P\ 0.01), and Uoral (Cau r = -0.61,
P\ 0.01; SA r = -0.73, P\ 0.01). Urinary C-peptide
corresponded well to plasma C-peptide AUC (Cau
r = 0.45, P\ 0.01; SA r = 0.33, P\ 0.05) and OMM
estimate of renal C-peptide secretion (r = 0.42, P\ 0.01).
In general, glucose excretion plasma threshold for the
presence of glucose in urine was *10–10.5 mmol L-1
in non-T2D individuals, but not measurable in T2D
individuals. Renal glucose secretion during OGTT did not
influence OMM indices in general nor in T2D patients
(renal clearance range 0–2.1 %, with median 0.2 % of
plasma glucose AUC). C-indices of urinary glucose to
detect various stages of glucose intolerance were excellent
(Cau 0.83–0.98; SA 0.75–0.89). The limited role of renal
glucose secretion validates the neglecting of urinary glu-
cose secretion in kinetic models of glucose homeostasis
using plasma glucose concentrations. Both C-peptide and
glucose in urine collected during OGTT might be used as
non-invasive measures for endogenous insulin secretion
and glucose tolerance state.
Keywords Type 2 diabetes  OGTT  Oral minimal
model  C-peptide  Glucose  South Asian
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DI Disposition Index
eGFR Estimated glomerular filtration rate
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MDRD Modification of diet in renal disease
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Introduction
Mathematical approaches based on compartmental phar-
macokinetic/pharmacodynamic (PK/PD) principles are
used to describe the biphasic glucose–insulin system in oral
function tests [1, 2], with the oral minimal model (OMM)
as one of the most widely accepted approaches [3].
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However, the contribution of renal clearance of endogenous
glucose, insulin, and C-peptide during oral glucose toler-
ance test (OGTT) in various stages of glucose tolerance
remains largely unclear. As renal extraction of insulin is
negligible [4], we focused on the relationship between
plasma and urine concentrations of both C-peptide and
glucose, collected during OGTT in the post-glucose load
phase. This was performed in families to obtain groups with
different risk for T2D, and we recruited families of South
Asian and Caucasian origin to enable generalization of our
findings. Especially, South Asians with T2D may be at high
risk for chronic kidney disease [5]. We questioned to which
degree C-peptide and glucose excretion in urine influence
OGTT-based plasma indices. Moreover, we compared the
OMM-derived estimates of renal C-peptide excretion with
actual urinary C-peptide concentration. In addition, renal
loss of glucose is not taken into consideration in OMM, and
the extent to which renal clearance might require correction
of plasma-derived OMM calculations is unknown.
Methods
Subjects and anthropometric data
Patients were recruited from South Asian and Caucasian
families with high risk of T2D after family screening from
the Outpatient Clinic of the Erasmus Medical University
Centre as described previously [6]. The first-degree rela-
tives of patients with T2D attending our Clinic (index
cases), who did not have T2D were recruited from 36 South
Asian families and 24 Caucasian families, with 2 genera-
tions taken into account. Data were obtained from 57 (M29
F28) South Asians and 64 (M24 F40) Caucasians who all
underwent an OGTT. Index cases were on metformin use
only and had at least one sibling with T2D. Informed
written consent to the study was obtained from all partic-
ipants. The study protocol was approved by the Erasmus
University Medical Center Medical Ethics Review Board.
All procedures followed were in accordance with the eth-
ical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2008.
OGTT
Venous blood was drawn via an intravenous canula, at
time-points 60 and 15 min before 75 g glucose load and
15, 30, 45, 60, 90, 120, 150, 180, and 210 min after glucose
load to measure glucose, insulin, and C-peptide concen-
trations. The WHO criteria for the OGTT were used to
define normal glucose tolerance (NGT), impaired fasting
glucose and/or impaired glucose tolerance (IFG/IGT), or
Type 2 diabetes (T2D) status among subjects. After emp-
tying their bladder prior to glucose load, urine was col-
lected until 210 min after glucose load. As there were no
significant differences between baseline values of plasma
glucose, insulin, or C-peptide obtained at -60 min or
-15 min, and as -60 min was sampled before our study
subjects had emptied their bladder prior to glucose load, we
chose -60 min as the representative baseline value. In 7 of
18 Caucasians with T2D, urine was not collected, because
it was not included in our protocol at that time. As this
group did not significantly differ from the remaining group,
we used data of n = 18 for all plasma indices, but data of
n = 11 for all analyses with urinary glucose and C-peptide
measurements in Caucasians.
Immunoassay
Plasma and urine glucose was measured by a hexokinase-
based method (Gluco-quant; Roche Diagnostics, Man-
nheim, Germany). Plasma and urine C-peptide, and plasma
insulin were measured separately by a competitive
chemiluminescent immunoassay, supplied by Euro/DPC.
The assay was performed on a DPC Immulite 2000 ana-
lyzer (Euro/DPC) according to the manufacturer’s recom-
mended protocol. Serum creatinine was measured with an
enzymatic procedure based on creatinine conversion with
the Creatinine Plus assay on a Roche/Hitachi analyzer.
Urine creatinine was measured based on the Jaffe alkaline
picrate method.
Calculations for OMM
The OMM was used to describe the plasma glucose,
insulin, and C-peptide concentrations after oral glucose
stimulus [7]. With C-peptide minimal model, we assessed
parameters for beta-cell function: basal responsivity of
beta-cells due to basal glucose potentiation Ubasal(min
-1),
static responsivity of beta-cells due to glucose potentiation
Ustatic (10
-9 min-1), dynamic responsivity of beta-cells
due to glucose potentiation Udynamic (10
-9), total respon-
sivity of beta-cells due to glucose potentiation Uoral
(10-9 min-1), and delay in response to glucose potentia-
tion T (min). With glucose minimal model, we assessed
parameters for insulin sensitivity, insulin sensitivity SI
(10-5 dL kg-1 min-1 per pM). Parameters from both
models were multiplied with each other for calculation of
disposition indices (DI), which are beta-cell function
measures corrected for insulin sensitivity: DIbasal =
Ubasal*SI, DIstatic = Ustatic*SI, DIdynamic = Udynamic*SI, and
DIoral = Uoral*SI. Parameters of OMM were estimated with
SAAM2 software [8]. Incremental plasma AUC of
C-peptide and glucose within a given time period was
calculated according to trapezoidal rule, with subtraction of
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basal concentration. For urinary glucose, we estimated
plasma glucose threshold (when exceeded glucose in urine
is present) separately among both our T2D and non-T2D
(NGT ? IFG/IGT) groups; we calculated plasma glucose
AUCs from 8.5 to 11.5 mmol L-1 with an interval of
0.5 mmol L-1 to detect the most suitable plasma glucose
threshold. Stepwise exclusion was performed of T2D and
non-T2D individuals, based on whether their plasma glu-
cose AUC was above a given threshold or not. Also, to
determine the relative renal loss of glucose from total
plasma glucose AUC, renal clearance of glucose was cal-
culated with absolute amount of urinary glucose/total
plasma glucose AUC. For comparison with urinary
C-peptide, we used AUC from flux k01 (Fig. 1) from
OMM, representing irreversibly metabolized C-peptide
from central compartment. Estimated glomerular filtration
rate (eGFR) was estimated with the modification of diet in
renal disease (MDRD) formula [9, 10].
Statistical analyses
Data analysis
Data are expressed as mean ± SEM, or indicated other-
wise. Comparisons within the subgroups of the ethnicities
were done with ANOVA, with the other two subgroups of
same ethnicity and with the corresponding other ethnic
subgroup. Differences were considered statistically signif-
icant when the two-sided P value was \0.0125. Urinary
glucose and C-peptide were correlated with plasma indices,
with Spearman correlation within each ethnicity, with
significance at P value \0.05. For urinary glucose and
C-peptide concentrations, AUC of receiver-operated char-
acteristics (ROC) curves (concordance indices or c-indi-
ces), adjusted for family ties by binary logistic regression
analysis [11], were calculated to detect IFG/IGT and/or
T2D status. All statistical tests were conducted with the use
of SPSS, version 15.0, for Windows (SPSS Inc., Chicago,
IL, USA).
Results
Baseline characteristics
Baseline characteristics are shown in Table 1 and incre-
mental plasma AUC of primary data glucose, insulin, and
C-peptide during OGTT in Fig. 2. South Asian T2D indi-
viduals were younger (P = 0.004), shorter (P\ 0.001),
and weighed less (P = 0.005) than Caucasian T2D indi-
viduals. W/H increased from NGT to T2D in Caucasians
(P = 0.003), but not in South Asians. In both ethnicities,
incremental plasma glucose AUCs from NGT or IFG/IGT
were significantly lower than T2D (P\ 0.001). In both
ethnicities, no significant differences were found in incre-
mental plasma insulin AUC between NGT, IFG/IGT, and
T2D; however, a difference was found between South
Asian NGT and Caucasian NGT (P\ 0.01). In both eth-
nicities, no significant differences were found in incre-
mental plasma C-peptide AUC between NGT, IFG/IGT,
and T2D. In both ethnicities, no significant differences
were found in Ubasal between NGT, IFG/IGT, and T2D,
whereas, Udynamic, Ustatic, and Utotal decreased with
increasing glucose intolerance. No significant differences
were found in delay T. With OMM, we observed a decrease
in insulin sensitivity in both ethnicities with increasing
glucose intolerance (P\ 0.001); however, differences
were lower among the South Asian subgroups. All disposi-
tion indices decreased with increasing glucose intolerance.
Overall, South Asian NGT and IFG/IGT demonstrated
lower DI indices when compared to Caucasian NGT,
whereas those of South Asian T2D were higher than their
CP1 CP2
SR
k21
k12
k01
(a)
(b)
Fig. 1 a Two-compartment model of C-peptide kinetics that is
integrated in oral minimal model (OMM). SR is prehepatic insulin
secretion rate, based on C-peptide curve. CP1 represents the amount
of C-peptide in central compartment and CP2 the amount of
C-peptide in peripheral compartment. k21 and k12 are C-peptide
transfer rates between CP1 and CP2; k01 describes metabolization of
C-peptide from CP1. In this study, plasma AUC of CP1*k01, or OMM
flux k01, is related to actual measured C-peptide concentration in urine
during OGTT. Adapted from van Cauter et al. [1]. b Correlation
between C-peptide in urine and OMM flux k01. NGT (triangle), IFG/
IGT (square), and T2D (circle) subgroups for South Asian (closed)
and Caucasian (open) families
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Caucasian counterparts. In both ethnicities, glucose in
urine increased with increasing glucose intolerance; both
creatinine-unadjusted and adjusted urinary glucose in T2D
subgroup were significantly higher when compared to
NGT or IFG/IGT subgroups (P\ 0.001). In Caucasians,
creatinine adjusted C-peptide was higher in T2D when
compared to NGT and IFG/IGT combined (T test
P = 0.005); no differences were found among South
Asians.
Effect of renal glucose loss on plasma-derived OMM
indices
The absolute amount of glucose concentration collected in
urine voids of T2D patients did not influence glucose
minimal model measurements, as a result of the small
variation of renal clearance (range 0–2.1 %, with median
0.2 % of total plasma glucose AUC).
Relation urine markers with plasma indices
of C-peptide and glucose, OMM, and eGFR
Relationships between urinary glucose and C-peptide with
plasma indices in both ethnicities can be found in Table 2.
In both ethnicities, urinary glucose was positively associ-
ated with plasma glucose AUC and negatively associated
with SI and DI values. In both ethnicities, urinary C-peptide
was positively associated with plasma C-peptide AUC.
Plasma AUC of OMM flux k01 reflecting C-peptide from
central compartment that is irreversibly metabolized, cor-
related with creatinine-adjusted urinary C-peptide (Fig. 2;
r = 0.42; P\ 0.01). Creatinine-unadjusted and adjusted
urinary glucose as well as C-peptide had no significant
correlation with eGFR.
Estimation of glucose threshold among non-T2D
and T2D subgroups
Our stepwise exclusion approach to estimate glucose
threshold during OGTT can be found in Table 3. It led to
glucose threshold of *10 mmol L-1 among Caucasian
NGT and IFG/IGT individuals. In South Asians, glucose
threshold for NGT and IFG/IGT individuals did not differ
much, being *10.5 mmol L-1. Glucose threshold during
OGTT varied considerably among T2D patients from both
ethnicities and was therefore not assessable.
ROC values of urine markers for detection
of glucose tolerance state
We examined the areas under ROC curves of glucose and
C-peptide in urine unadjusted as well as adjusted for cre-
atinine (adjusted are the values between brackets),
respectively. We have found clear differences between the
two ethnicities and therefore performed separate analyses.
Urinary glucose concentration demonstrated high capabil-
ity to discriminate between T2D and the combination of the
Fig. 2 Incremental plasma AUC of glucose, insulin and C-peptide
during 210 min OGTT (mean ± SEM) among WHO OGTT sub-
groups with normal glucose tolerance (NGT), impaired fasting
glucose and/or impaired glucose tolerance (IFG/IGT) and Type 2
diabetes (T2D) from South Asian (SA) or Caucasian (Cau) origin.
Incr. plasma glucose AUC; SA NGT versus T2D SA P\ 0.001, SA
IFG/IGT versus T2D P\ 0.001, Cau NGT versus Cau T2D
P\ 0.001, CauIFG/IGT versus Cau T2D P\ 0.001. Incr. plasma
insulin AUC; SA NGT versus Cau NGT P\ 0.01. Please note
different scale in Y-axis for insulin and C-peptide.
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other two subgroups (NGT and IFG/IGT), 0.976 (0.996) in
Caucasians and 0.893 (0.898) in South Asians, respec-
tively. We also calculated c-indices of urinary glucose for
NGT versus the combination of IFG/IGT and T2D, 0.904
(0.908) in Caucasians and 0.894 (0.877) in South Asians,
and c-indices for NGT versus the IFG/IGT subgroup, 0.826
(0.827) in Caucasians and 0.748 (0.736) in South Asians,
respectively (Fig. 3).
The c-indices of urinary C-peptide concentration for the
detection of glucose tolerance status were for discrimina-
tion between T2D and the combination of two other sub-
groups, 0.658 (0.742) in Caucasians and 0.503 (0.565) in
South Asians, respectively. The c-indices for NGT versus
the combination of IFG/IGT and T2D were 0.692 (0.733)
in Caucasians and 0.556 (0.584) in South Asians. The
c-indices for NGT versus IFG/IGT were 0.792 (0.792) in
Caucasians and 0.595 (0.599) in South Asians, respectively
(Fig. 3).
Discussion
We found that urinary C-peptide collected during OGTT
correlated with plasma C-peptide indices and OMM-
derived estimates of renal C-peptide excretion. Urinary
glucose collected during OGTT also correlated well with
plasma indices, especially with plasma glucose AUC.
Urinary glucose was mainly present in urine of patients
with T2D; however, the loss of glucose in the urine was too
small to influence general OMM calculations. Among the
patients with T2D, the urinary glucose concentration
showed large variation but discriminated well between
normal and abnormal glucose tolerance.
Both glucose minimal model and C-peptide minimal
model assess plasma glucose concentrations during OGTT
with the first model also applying an area under the curve
constraint; the amount of circulating glucose is expected to
be a fixed parameter based on the amount of glucose load
used as stimulus. The knowledge about the effects of
dynamic glucose loss on OMM-based parameters due to
renal handling after stimulus is limited [7]. We hypothe-
sized that the variance of the urinary glucose excretion
could be a serious confounder, but we found that renal loss
of glucose does not influence OMM-based parameters of
insulin sensitivity and beta-cell function. This finding is
highly relevant for glucose homeostasis based kinetic
models in general.
Overnight, 24-h fasting, and after a mixed meal, urine
collection studies demonstrated the value of urinary
C-peptide as non-invasive measure for endogenous insulin
secretion in people with and without diabetes [12–17]. As
stricter metabolic control affects urinary C-peptide, it
might be of use to follow-up the insulin secretory function
[18–20]. In line, we found that during OGTT, urinary
C-peptide correlated well with plasma values reflecting the
endogenous pancreatic secretion. For urinary C-peptide, we
did not observe a relationship between eGFR MDRD. This
is in agreement with previous studies, where the presence
of micro albuminuria or renal impairment with reduced
filtration rate did not alter the relationship between urinary
and plasma C-peptide [21, 22].
Glucose is cleared by the kidney and predominantly
reabsorbed by the sodium-glucose co-transporter 2
(SGLT2) in the proximal tubules. The urinary glucose
excretion threshold is believed to be around 10 mmol L-1
in individuals without T2D [23, 24], which is in accordance
with our estimations, with the exception of our individuals
with T2D. Our patients with T2D did not use SGLT2
inhibitors. With clamp steady-state studies, it was demon-
strated that a glucose threshold is not applicable to indi-
viduals with T2D due to a large variation in their glucose
excretion; and glucosuria is present even when treated
Table 2 Spearman correlation between urine markers and plasma indices
Urine markers Plasma indices
Incr C-peptide AUC Incr. glucose AUC SI Udynamic Ustatic DIdynamic DIstatic
South Asians
Glucose urine -0.023 0.757** -0.459** -0.578** -0.774** -0.687** -0.730**
Glucose/creatinine ratio urine -0.059 0.690** -0.414** -0.565** -0.727** -0.653** -0.674**
C-peptide urine 0.331* 0.170 -0.151 0.153 0.036 0.010 -0.060
C-peptide/creatinine ratio urine 0.301* 0.069 -0.148 0.100 0.068 -0.057 -0.002
Caucasians
Glucose urine 0.175 0.669** -0.639** -0.208 -0.571** -0.663** -0.763**
Glucose/creatinine ratio urine 0.036 0.644** -0.513** -0.412** -0.610** -0.687** -0.656**
C-peptide urine 0.485** 0.346* -0.458** 0.178 -0.039 -0.269 -0.398**
C-peptide/creatinine ratio urine 0.453** 0.254 -0.202 -0.055 -0.053 -0.198 -0.168
* P\ 0.05, ** P\ 0.01
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Table 3 Two groups, one with
and one without glucose in urine
CaucasiansA South Asians
N (stepwise) Glucose AUC N (stepwise) Glucose AUC
Threshold 8.5 mmol L-1
Urine glucose-
Non-T2D 3 28.8 ± 14.7 2 71.25 ± 57.0
T2D 0 0 1 33.8
Urine glucose?
Non-T2D 19 116.6 ± 29.3 14 116.2 ± 28.9
T2D 11 1012.9 ± 143.4 20 684.5 ± 107.0
Threshold 9 mmol L-1
Urine glucose-
Non-T2D 2 17.25 ± 6.0 2 41.3 ± 37.5
T2D 0 0 1 12.0
Urine glucose?
Non-T2D 16 103.6 ± 28.0 12 99.7 ± 26.0
T2D 11 922.7 ± 139.1 20 614.0 ± 102.2
Threshold 9.5 mmol L-1
Urine glucose-
Non-T2D 2 2.25 ± 1.50 1 45.8
T2D 0 0 0 0
Urine glucose?
Non-T2D 11 112.1 ± 28.5 11 75.8 ± 23.0
T2D 11 837.8 ± 133.8 20 545.1 ± 97.3
Threshold 10 mmol L-1
Urine glucose-
Non-T2D 0 0 1 16.5
T2D 0 0 0 0
Urine glucose?
Non-T2D 9 99.0 ± 25.6 8 67.5 ± 22.4
T2D 11 759.3 ± 128.5 20 480.3 ± 91.8
Threshold 10.5 mmol L-1
Urine glucose-
Non-T2D 0 0 0 0
T2D 0 0 0 0
Urine glucose?
Non-T2D 8 77.6 ± 20.6 7 46.9 ± 18.6
T2D 11 683.1 ± 123.2 20 420.5 ± 85.8
Threshold 11.0 mmol L-1
Urine glucose-
Non-T2D 0 0 0 0
T2D 0 0 0 0
Urine glucose?
Non-T2D 8 53.3 ± 16.5 7 25.9 ± 13.9
T2D 11 608.8 ± 117.8 19 383.8 ± 81.4
Threshold 11.5 mmol L-1
Urine glucose-
Non-T2D 0 0 0 0
T2D 0 0 0 0
Urine glucose?
Non-T2D 7 38.6 ± 13.4 4 21.2 ± 13.0
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patients with T2D return to euglycemic conditions [25, 26].
Hence, using the OGTT the post-glucose-load urinary
glucose concentration may be useful as non-invasive
marker to detect abnormal glucose tolerance, but it is not
suited to monitor treatment.
The strength of the present study lies in the fact that we
used OMM and assessed urine parameters in two different
ethnicities and in all stages of glucose tolerance. Among
the weaknesses of our study are the limited sample size, the
limited possibilities to translate our findings of the
extended OGTT into clinical applications and using esti-
mate eGFR MDRD instead of measuring GFR directly as a
measure for renal function. Although our groups were
relatively small, differences between subgroups and eth-
nicities became apparent with this relatively simple and
low-cost test procedure. In contrast to the customary 24-h
urine collections obtained at home, we collected urine in
the hospital setting, during an extended version of OGTT.
Validity of reduced amount of sampling and sampling time
after stimulus has been demonstrated previously in healthy
individuals, resulting in a more practical application of
OMM [27]. We were also able to reduce amount of sam-
pling, as we found no significant differences between
plasma indices obtained from our above-described final
210 min-post-glucose load nine samples OGTT versus an
earlier performed pilot with 210 min-post-glucose load 13
samples OGTT, which also included sampling at t = 5,
t = 10, t = 20 and t = 25 min (data not shown). The
participants in our study had no severe kidney failure and
no history of renal disease.
In conclusion, urinary C-peptide corresponded well to
OMM-derived estimates of renal C-peptide clearance and
the renal glucose secretion during OGTT did not influence
OMM indices.
Table 3 continued
CaucasiansA South Asians
N (stepwise) Glucose AUC N (stepwise) Glucose AUC
T2D 11 538.9 ± 111.8 17 367.0 ± 78.7
With increasing glucose threshold, stepwise exclusion was performed separately among non-T2D
(NGT ? IFG/IGT) and T2D subgroups, based on their absence of having above threshold glucose AUC
(mean ± SEM)
A Caucasian T2D n = 11, for reasons mentioned in methods section
Fig. 3 a, b Receiver-operated characteristics (ROC) curve for
discriminatory ability between individuals with normal glucose
tolerance (NGT) versus impaired fasting glucose/impaired glucose
tolerance (IFG/IGT) with urinary glucose (closed line) or C-peptide
(dashed line) concentration obtained from urine collected during
OGTT (both unadjusted for urine creatinine), in Caucasians (a) and
South Asians (b)
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